Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma.

Blood advances·2026
Same author

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.

The Lancet. Haematology·2026
Same author

Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.

The Lancet. Haematology·2026
Same author

Occult hepatitis B virus infection status is not associated with impaired efficacy of anti-CD19 CAR-T-cell therapy for lymphoma and shows a distinct immune toxicity profile: Results from the CART-SIE study.

HemaSphere·2026

Related Experiment Videos

Lenalidomide in diffuse large B-cell lymphomas.

Annalisa Chiappella1, Umberto Vitolo

  • 1Hematology 2, San Giovanni Battista Hospital and University, c.so Bramante 88, 10126 Torino, Italy.

Advances in Hematology
|July 14, 2012
PubMed
Summary
This summary is machine-generated.

Lenalidomide shows promise for treating Diffuse Large B-cell Lymphoma (DLBCL), a common Non-Hodgkin Lymphoma (NHL). It offers an active option for relapsed or refractory aggressive NHL with manageable side effects.

Related Experiment Videos

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Diffuse Large B-cell Lymphoma (DLBCL) is the most common Non-Hodgkin Lymphoma (NHL).
  • Standard R-CHOP chemoimmunotherapy improves outcomes but 40% of patients relapse.
  • Lenalidomide is an immunomodulatory drug with direct anti-tumor effects and immune-modulating properties.

Purpose of the Study:

  • To review clinical trials on lenalidomide for DLBCL.
  • To evaluate lenalidomide's efficacy and safety in relapsed/refractory aggressive NHL.
  • To discuss lenalidomide's potential in first-line treatment.

Main Methods:

  • Review of relevant clinical trials.
  • Analysis of monotherapy and combination therapy data.
  • Assessment of safety, feasibility, and efficacy.

Main Results:

  • Lenalidomide monotherapy demonstrated activity with acceptable toxicity in relapsed/refractory aggressive NHL.
  • Preliminary data suggest lenalidomide's role in both DLBCL cell-of-origin subtypes.
  • Early data on lenalidomide combined with R-CHOP in first-line settings are promising.

Conclusions:

  • Lenalidomide is an active agent for relapsed/refractory aggressive NHL.
  • Further investigation into lenalidomide's role in first-line DLBCL treatment is warranted.
  • Lenalidomide offers a potential therapeutic option for DLBCL patients with unmet needs.